[{"orgOrder":0,"company":"Bambusa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"BBT001","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Bambusa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bambusa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bambusa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bambusa Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Series A Financing","leadProduct":"BBT001","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Bambusa Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Bambusa Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Bambusa Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Bambusa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BBT002","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Bambusa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bambusa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bambusa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bambusa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"BBT001","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Bambusa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bambusa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bambusa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bambusa Therapeutics","sponsor":"Athos KG | RA Capital Management | INCE Capital | Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Series A Financing","leadProduct":"BBT003","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Bambusa Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bambusa Therapeutics \/ Athos KG | RA Capital Management | INCE Capital | Redmile Group","highestDevelopmentStatusID":"4","companyTruncated":"Bambusa Therapeutics \/ Athos KG | RA Capital Management | INCE Capital | Redmile Group"}]